Share Name Share Symbol Market Type Share ISIN Share Description
Plant Impact LSE:PIM London Ordinary Share GB00B1F4K366 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 27.75p 27.00p 28.50p 27.75p 27.75p 27.75p 3,000 07:32:13
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Chemicals 7.2 -1.2 -0.9 - 26.25

Plant Impact (PIM) Latest News

More Plant Impact News
Plant Impact Takeover Rumours

Plant Impact (PIM) Share Charts

1 Year Plant Impact Chart

1 Year Plant Impact Chart

1 Month Plant Impact Chart

1 Month Plant Impact Chart

Intraday Plant Impact Chart

Intraday Plant Impact Chart

Plant Impact (PIM) Discussions and Chat

Plant Impact Forums and Chat

Date Time Title Posts
25/9/201712:56Plant Impact - Increasing crop capacity1,242
09/1/201722:21Attended AGM..1
14/5/201415:15PIM - Built on sand?4
17/9/201319:20PLANT IMPACT : transforming agriculture with eco-friendly solutions1,661
15/12/201108:26Plant Impact plc606

Add a New Thread

Plant Impact (PIM) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
07:35:0528.503,000855.00O
View all Plant Impact trades in real-time

Plant Impact (PIM) Top Chat Posts

DateSubject
26/9/2017
09:20
Plant Impact Daily Update: Plant Impact is listed in the Chemicals sector of the London Stock Exchange with ticker PIM. The last closing price for Plant Impact was 27.75p.
Plant Impact has a 4 week average price of 26.75p and a 12 week average price of 26.75p.
The 1 year high share price is 55p while the 1 year low share price is currently 26.75p.
There are currently 94,598,625 shares in issue and the average daily traded volume is 34,373 shares. The market capitalisation of Plant Impact is £26,251,118.44.
15/9/2017
17:02
wan: Visionon...I do, or at least I did, like Bayer, but change is obviously coming from the merger with Monsanto (who some people and investors hate!), so I have been monitoring events and commentary to see how things might change. Obviously the merger would imply that Bayer's R&D focus will probably change, indeed recent news flow and commentary also suggests that might well be the case. It is possible that Bayer do not want any more distractions whilst the merger is being investigated, but again and as the recent news flow indicates, they are not exactly doing nothing in the interim of concluding the deal. I suppose what I am ultimately saying is that, I have tweaked my view, in that I am not completely relying on Bayer to provide further success beyond Veritas (I think the share price is saying the same), and I too would welcome a good slug of income coming from another source. Certainly the pipeline would suggest that this has a good possibility happening. It is also possible that Bayer don't want to give up on certain aspects of PI's products, developments, IP, or indeed the replicable R&D platform, not to mention the collaboration with Ghent University that grants Plant Impact exclusive development access and a licensing option for some very interesting and novel compounds to improve drought tolerance in crops (hence things are taking a while to conclude, otherwise we would surely have some answers by now if it was just about Veritas/Fortalis?). Arguably, PI's portfolio would help counter some of the more unpopular aspects of Monsanto! So, it might not be a bad thing, one way or another, that contract discussions are taking some time to conclude. Food for thought at least!
29/8/2017
16:04
wan: Buywell...With respect, I was not criticising his criticism of the share price performance, and I did say that I appreciated the frustration being felt.
08/8/2017
10:53
glenglen: I am glad to see others are not too impressed with the fall in the share price of PI - buywell3 and rlivesy's comments echo my thoughts. I myself amin for long term more from stubbornness than fundamentals at this stage - my stake is reasonably small. I note the optimism of Wan and others and am hoping, I suppose, that they are right. The above being said, the concern on the share price is understandable (I share it) as there is all this optimism from the Board who are being paid substantial salaries but are not performing - sure they have reasons for non-performance but for how long is this going to last. With all this R&D going on it seems to me PI is really a faculty in a university except the students are getting paid whether they perform or not. The bottom line is the share price drop is substantial and the price at the moment does not inspire confidence - the Board needs to address these concerns and give their reasoned opinion as to why just over a year ago the price was 60p and has halved to 30p and what they are actually doing to rectify matters? I do not think that is an unreasonable request.
04/8/2017
07:54
wan: Glen....None of us can get it right all the time....including Midas! I bought in well ahead of the Midas tip and I have also bought at higher prices than today's share price. FWIW, I am heavily invested here, so I am feeling the pain and disappointment too, but I believe that managements interests are well aligned with that of shareholders, so the fall in the share price is being felt there too! It's worth considering that the biostimulant sector has changed considerably since the early years, evidenced by the large players entering the sector in a committed way, as indeed evidenced by deals such as PI's with Bayer, and with Bayer referring to PI as “Our partner company". I have no doubt that Bayer's rationale to partner with PI went way beyond that of Veritas alone. I am therefore keen for PI to push on with their R&D and indeed accelerate the development of their current near term product pipeline. In my view, the current situation is a setback not a complete failure of the business model, so I see this as a setback on route to better things. For sure lessons will have been learned and changes made, but that is the nature of life and most certainly the nature of business!
01/8/2017
09:22
wan: I note we now have a new (presumably 12 month) broker price target of 47p, which is interesting given the comments above regarding the Value Creation Plan (VCP) and the relevant share price hurdles etc. In my view, with the 50p share price hurdle and gross profit target having already been met, clearly the next target is maintaining a share price above 50p in order that it can be exercised, with 70p being the next target......let's hope that one is achievable and, at the very least, holds. It should certainly serve to focus minds! Geographic expansion obviously came a bit late to help matters, but I sense growth guidance overall is now more conservative compared to previous guidance. Nonetheless, geographic expansion is happening and hopefully this will be felt more than the current (conservative?) guidance going forwards. Brazil will remain a large and important market though, but nonetheless, the percentage share of revenues from Veritas in Brazil should reduce going forwards as sales expansion elsewhere gains momentum and(hopefully)other products make their way through to commercialisation proper. I have now had time to catch up with Bayer's Results commentary in detail, and in my view, for the best indication and insights as to what happened on the ground in Brazil, comes via the Conference Call, namely the Q & A section (pages 6 - 23 of the transcript below), where some interesting questions were raised and effectively answered. In short, Bayer do appear to have locked the situation down and further rolled out their sophisticated inventory management system (to the extent that it should prevent a similar situation going forwards). Importantly, current demand is described and forecast as being "robust". Transcript of Bayer's Conference Call - hxxp://www.investor.bayer.de/securedl/15519
28/7/2017
08:52
wan: Visionon...The earliest vesting date is 20th November, but the performance criteria will ultimately dictate at what date vesting can be achieved, however, the VCP option is not capable of exercise for another two years after the vesting date, and it is the exercise date to which the restriction you refer to applies - "Once (and to the extent) vested, a VCP-Option will generally not be capable of exercise for a further two years after the vesting date (except in the event of certain corporate events or in the case of certain leavers as described below). However, if by the permitted exercise date of a VCP-Option (or part of it), the Share Price is more than 30% below the Share Price Hurdle which triggered vesting of that VCP-Option (or that part of it), exercise of that VCP-Option (or part) is not permitted until the Share Price again achieves that Share Price Hurdle on average for at least 20 consecutive dealing days." hxxp://www.plantimpact.com/~/media/Files/P/Plant-Impact/reports-and-presentations/2014/20172-plantimpact-nom-141027.pdf
26/7/2017
22:56
bigglesbingham: The wording is vague. It says "by" vesting I think it means "at" vesting date. If it was "by" vetting date it implies if share price went below 35p at any time then it could be delayed. If it means "at" vesting date if the price recovers to above 35 p but below 50p at vesting date then he cannot vest. The price did go below 35p after Nov 2014 (I think)so if that's the case the issuance price is irrelevant. Or have I misread it??
17/7/2017
10:43
horace_h: I'd pretty much entirely agree with that Wan, especially the commitment of the existing institutional investor. There's also the sentence: "The Company now has a significant number of product development projects in the final stages of pre-commercial testing, and the Board has determined that it is in the best interest of shareholders to sustain the momentum of the R&D supporting these projects." In one sense, that subjective non-specific comment can be viewed as "predictable sugar coating" but, if "final stages" means "success sooner rather than later" all thoughts of prime dependence on one product will go away. I held when the share price topped 60p in the hope that the release of the Wheat Suite of products would propel the share price closer to the option exercise territory that PIM Board members financial reward kicked in and all shareholders enjoy gravy with their green vegetables. I've lost a lot of profit for now but the low level of selling, as pointed out by Cerrito, keeps me on an even keel. I've little doubt that "ShortWell" will disagree - for whatever motivation - that's the market.
11/4/2017
13:16
horace_h: The last two wonderful summers in the US Midwest have significantly increased the Supply of Corn, Wheat and Soyabeans and thus depressed the price. For those that read charts based solely on price action (Supply and Demand), Soyabean Futures are currently sitting in a Monthly Demand zone and a price rise is the higher probability trade. The debate above as to the significance of that, is interesting and we'll all form our own conclusions as to the relevance of the product price. Having said that, I really don't understand why Mthead is still in this share. When (I clearly had more spare time than sense) I looked at his/her ADVFN posts on PIM. The last time he/she said something positive was 2011, although there was a reference to having a break-even holding price of 31 when another poster was bemoaning buying at 60p. Everything else has been critical or negative. You're obviously entirely welcome to express your opinion but six years of negativity appears a bizarre use of time. Before I get the rosy-tinted label, I AM disappointed that a commercial Wheat product hasn't appeared quicker but the share price and everything else is a vast improvement since John Brubaker assumed control - in 2011. H & T is probably right to observe that the share is "tradeable" until something significant happens but I see PIM as an investment. If I'd sold when we were in the vicinity of 65p, I'd be very pleased and would have bought back in somewhere around now. IF PIM had been (or is) bought out at far higher than 65p, before I got back in, I'd feel stupid. That's obviously the game. I appreciate Wan and others sharing their diligent research and I personally value his objectivity. Yes, he is mostly positive but why wouldn't he be if invested in a share that he (and I) feel has the potential to significantly rise in price. I also appreciate genuine reports on the share that are NOT supportive of a price rise to see if the upside is too limited to stay. I'm not going to speculate why you are so consistently negative - it's not as if you can short the share. As noted, if all you want to do is knock the company and its management that dictate the success of your investment then that's up to you. Have fun but please try and spread a little sunshine occasionally...
22/2/2017
09:58
glenglen: I am new to this investing lark and will admit I know little about soybean production/exports and related topics. Bought into PIM in 2015 after reading a good report on it- the company was going places so I thought I will get "in on the action" - Took a punt in effect. All I need to know is where is this company going for me as a shareholder? Will the share price ever increase. For 2 years I have read all these "positives" which is good but share price drops and seems to merely hover round 45p - 50p My risk/fault/whatever I fully accept but will there ever be a bonanza coming our way? Is it the intention (long term or otherwise) that Bayer (or someone of the same ilk) will come along and buy them - hopefully offering more than 50p? Long term I do not have a problem with but can someone shed some light on how long that term might just be?
Plant Impact share price data is direct from the London Stock Exchange
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:30 V: D:20170926 14:46:43